MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Low explanatory power (R² 0.09) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $16.1B— | $12.2B-24.3% | $13.1B+7.8% | $14.2B+8.3% | $14.3B+1.0% |
| EPS (dil.) | $71.97— | $38.22-46.9% | $34.77-9.0% | $38.34+10.3% | $41.48+8.2% |
| Free Cash Flow | $6.5B— | $4.4B-32.2% | $3.7B-17.1% | $3.7B-0.1% | $4.1B+11.3% |
| Gross Margin | 83.1% | 86.0%+2.9pp | 82.9%-3.1pp | 86.1%+3.2pp | 85.4%-0.8pp |
| Operating Margin | 55.7% | 44.2%-11.4pp | 33.2%-11.1pp | 28.1%-5.1pp | 24.9%-3.2pp |
| Net Margin | 50.2% | 35.6%-14.6pp | 30.1%-5.5pp | 31.1%+0.9pp | 31.4%+0.3pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$6.6M over 180 days (0 open-market buys, 33 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 6.2%/yr (revenue basis).
Base free cash flow $3.8B (avg FY2023–FY2025; latest year $4.1B) · equity value $95.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $842 (last qtr, 18 analysts) → $869 (last mo, 9) (+3.2%).
Buy-rated share 68% → 66% over ~3 months (-2pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $16.42 | $20.07 | +22.2% |
| Jul 2026 | $10.16 | $14.29 | +40.6% |
| Apr 2026 | $8.91 | $9.47 | +6.3% |
| Jan 2026 | $10.74 | $11.44 | +6.5% |
| Oct 2025 | $9.65 | $11.83 | +22.6% |
| Aug 2025 | $8.43 | $12.89 | +52.9% |
| Apr 2025 | $8.62 | $8.22 | -4.6% |
| Feb 2025 | $11.21 | $12.07 | +7.7% |
The QScore of 53 for Regeneron Pharmaceuticals indicates a neutral outlook, driven by strong momentum with a 12-month return of 39.5% and a bullish 50-day versus 200-day moving average. The stock's profitability also scores high, with a return on equity of 15.1% and a gross margin of 85.8%. However, the growth category scores lower, reflecting modest revenue growth of 1.0% and a relatively high valuation, with a P/E of 19.7. The long-term and short-term scores are relatively aligned, with only a 4-point difference.